29. Hoppe B.S. et al. Consolidative proton therapy after chemotherapy for patients with Hodgkin lymphoma // Annals of Oncology. 2017. Vol. 28, № 9. P. 2179-2184.
30. Tseng Y.D. et al. Evidence-based Review on the Use of Proton Therapy in Lymphoma From the Particle Therapy Cooperative Group (PTCOG) Lymphoma Subcommittee // International Journal of Radiation Oncology Biology Physics. Elsevier Inc., 2017. Vol. 99, № 4. P. 825-842.
31. Engert A. et al. Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin’s lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial. // Lancet. 2012. Vol. 379, № 9828. P. 1791-1799.
32. Sieber M. et al. 14-Day variant of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone regimen in advanced-stage Hodgkin’s lymphoma: Results of a pilot study of the German Hodgkin’s Lymphoma Study Group // Journal of Clinical Oncology. 2003. Vol. 21, № 9. P. 1734-1739.
33. Gallamini A. et al. Consolidation radiotherapy could be omitted in advanced Hodgkin lymphoma with large nodal mass in complete metabolic response after ABVD. Final analysis of the randomized HD0607 trial // Hematol Oncol. Wiley, 2019. Vol. 37. P. 147-148.
34. Barrington S.F. et al. PET-CT for staging and early response: Results from the Response-Adapted Therapy in Advanced Hodgkin Lymphoma study // Blood. American Society of Hematology, 2016. Vol. 127, № 12. P. 1531-1538.
35. Wedgwood A., Younes A. Prophylactic use of filgrastim with ABVD and BEACOPP chemotherapy regimens for Hodgkin lymphoma. // Clin Lymphoma Myeloma. 2007. Vol. 8 Suppl 2. P. S63-6.
36. Engel C. et al. Acute hematologic toxicity and practicability of dose-intensified BEACOPP chemotherapy for advanced stage Hodgkin’s disease. German Hodgkin’s Lymphoma Study Group (GHSG). // Ann Oncol. 2000. Vol. 11, № 9. P. 1105-1114.
37. Hoppe R.T. et al. Hodgkin Lymphoma. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Version 1.2023. 2022. 95 p.
38. Yahalom J. et al. Modern radiation therapy for extranodal lymphomas: Field and dose guidelines from the international lymphoma radiation oncology group // Int J Radiat Oncol Biol Phys. Elsevier Inc., 2015. Vol. 92, № 1. P. 11-31.
39. Connors J.M. et al. Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin’s lymphoma // New England Journal of Medicine. N Engl J Med, 2018. Vol. 378, № 4. P. 331-344.
40. Ansell S.M. et al. Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin’s Lymphoma // N Engl J Med. N Engl J Med, 2022. Vol. 387, № 4. P. 310-320.
41. Mauz-Körholz C. et al. Procarbazine-free OEPA-COPDAC chemotherapy in boys and standard OPPA-COPP in girls have comparable effectiveness in pediatric Hodgkin’s lymphoma: The GPOH-HD-2002 study // Journal of Clinical Oncology. 2010. Vol. 28, № 23. P. 3680-3686.
42. Dörffel W. et al. Treatment of children and adolescents with hodgkin lymphoma without radiotherapy for patients in complete remission after chemotherapy: Final results of the multinational trial GPOH-HD95 // Journal of Clinical Oncology. 2013. Vol. 31, № 12. P. 1562-1568.
43. Hudson M.M., Constine L.S. Refining the role of radiation therapy in pediatric hodgkin lymphoma. // American Society Of Clinical Oncology Educational Book / ASCO. American Society Of Clinical Oncology. Meeting. From the Department of Oncology, Division of Cancer Survivorship, St. Jude’s Children’s Research Hospital, Memphis, TN; Departments of Radiation Oncology and Pediatrics, Philip Rubin Center for Cancer Survivorship, James P. Wilmot Cancer Center at Univers: American Society of Clinical Oncology, 2012. P. 616-620.
44. International Commission on Radiation Units and Measurments. Prescribing, Recording, and Reporting Photon Beam Therapy (Supplement to ICRU Report 50). 1999. 1-62 p.
45. Румянцев А.Г., Самочатова Е.В. Практическое руководство по детским болезням. Том 4. Гематология и онкология детского возраста / ed. Коколина В.Ф., Румянцев А.Г. Медпрактика-М., 2004. 792 p.
46. Borchmann S., Engert A., Böll B. Hodgkin lymphoma in elderly patients // Current Opinion in Oncology. Lippincott Williams and Wilkins, 2018. Vol. 30, № 5. P. 308-316.
47. Thyss A. et al. Hodgkin’s lymphoma in older patients: An orphan disease? // Mediterranean Journal of Hematology and Infectious Diseases. Universita Cattolica del Sacro Cuore, 2014. Vol. 6, № 1. P. 1-10.
48. Капланов К.Д. et al. Программа IVDG - возможный выбор первой линии терапии лимфомы Ходжкина у пациентов пожилого возраста с сопутствующими сердечно-сосудистыми и легочными заболеваниями // Клиническая онкогематология. 2017. Vol. 10, № 3. P. 358-365.
49. Fedele R. et al. Clinical Options in Relapsed or Refractory Hodgkin Lymphoma: An Updated Review. // J Immunol Res. 2015. Vol. 2015. P. 968212.
50. Nikolaenko L., Chen R., Herrera A.F. Current strategies for salvage treatment for relapsed classical Hodgkin lymphoma. // Ther Adv Hematol. 2017. Vol. 8, № 10. P. 293-302.
51. Mohty M. et al. Autologous haematopoietic stem cell mobilisation in multiple myeloma and lymphoma patients: A position statement from the European Group for Blood and Marrow Transplantation // Bone Marrow Transplantation. 2014.
52. Moskowitz A.J. et al. Pretransplantation functional imaging predicts outcome following autologous stem cell transplantation for relapsed and refractory Hodgkin lymphoma. // Blood. 2010. Vol. 116, № 23. P. 4934-4937.
53. Moskowitz C.H. et al. Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse. // Blood. 2018. Vol. 132, № 25. P. 2639-2642.
54. Chen R. et al. Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma. // Blood. 2016. Vol. 128, № 12. P. 1562-1566.